Navigation Links
Antisoma plc (UK) - Second lung cancer trial adds to positive data,on AS1404

Rebecca Skye Dietrich Buchanan Communications +44 (0)20 7466 5000

Brian Korb/Seth Lewis The Trout Group +1 646 378 2900

Antisoma disclaimer Certain matters discussed in this statement are forward looking statements that are subject to a number of risks and uncertainties that could cause actual results to differ materially from results, performance or achievements expressed or implied by such statements. These risks and uncertainties may be associated with product discovery and development, including statements regarding the company's clinical development programmes, the expected timing of clinical trials and regulatory filings. Such statements are based on management's current expectations, but actual results may differ materially.

Details of the second lung cancer study This trial was conducted as an open-label extension to the first, randomised study of AS1404 in lung cancer. As in the randomised study, patients were receiving first-line chemotherapy treatment for stage IIIb or IV non-small cell lung cancer. All patients received 1800 mg/m2 AS1404 in combination with carboplatin and paclitaxel. The trial was conducted at hospitals in Germany and New Zealand.

Background on AS1404 AS1404 (DMXAA) is a small-molecule vascular disrupting agent which targets the blood vessels that nourish tumours. The drug was discovered by Professors Bruce Baguley and William Denny and their teams at the Auckland Cancer Society Research Centre, University of Auckland, New Zealand. It was in-licensed by Antisoma from Cancer Research Ventures Limited (now Cancer Research Technology), the development and commercialisation company of the Cancer Research Campaign (now Cancer Research UK), in August 2001. CRUK had supported two phase I studies in the UK and New Zealand.

Background on Antisoma Based in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. Antisoma fills its development pipeline by acqui
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Data supporting three Antisoma programmes presented at AACR
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
5. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
8. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
9. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
10. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
11. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Antisoma plc Second lung cancer trial adds positive data
(Date:11/26/2014)... 26, 2014  Thoratec Corporation (NASDAQ: THOR ... therapies to save, support and restore failing hearts, said ... conferences. On Tuesday, December 2, the company ... Jaffray Healthcare Conference.  D. Keith Grossman , President ... the company beginning at 11:30 a.m., Eastern Standard Time ...
(Date:11/26/2014)... Company plc ("Perrigo") (NYSE: PRGO ; TASE), ... today announced the closing of Perrigo,s previously announced registered ... shares at a public offering price of $152.00 per ... purchase up to an additional 888,157 ordinary shares by ... representatives of the several underwriters. Perrigo ...
(Date:11/26/2014)... , Nov. 26, 2014 Lexicon Pharmaceuticals, ... the completion of previously announced concurrent financing transactions ... fees and estimated offering expenses, Lexicon anticipates net ...  The transactions consisted of: , a ... pursuant to a registration statement that has been ...
Breaking Medicine Technology:Thoratec Announces Presentations At Investor Conferences For December 2014 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 3Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 4Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3
(Date:11/27/2014)... Washington, DC (PRWEB) November 27, 2014 “LAB.C” ... Report, which features the latest and coolest technology products available ... NewsWatch, conducted the product review and shared with ... cable for iOS and Android devices. , Consumers love portability ... LAB.C. Their Cable Case for the iPhone5 and 5S ...
(Date:11/27/2014)... Dallas, Texas (PRWEB) November 27, 2014 ... research report on Global Insulin industry. For an ... including definition, classification, application, industry chain structure, industry ... report on global Insulin industry covers information ... manufacturing process, product cost structure and much more. ...
(Date:11/27/2014)... Allowing children to help with chores while ... give children responsibility, ownership, boosts self-esteem, and above all, helps ... the real question is, how do you encourage your children ... a study published by Child Development Journal, there is. The ... on a child’s willingness to lend a hand. , ...
(Date:11/27/2014)... November 27, 2014 RBSEO Services, ... search engine optimization service just at $99. RBSEO ... start-ups cannot afford costly search engine optimization service. ... keeping their affordablity and requirements into consideration. ... but it has not compromised with the service ...
(Date:11/27/2014)... 2014 Ethane Web Technologies, an ISO 9001: ... a 10% Christmas discount on PPC service. The discount will ... offer will begin on 1 December 2014 and remain valid ... offer, a PPC professional working at Ethane Web Technologies says, ... businesses, as this big discount would make the service quite ...
Breaking Medicine News(10 mins):Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 3Health News:RBSEO Services Announces SEO Services at $99 Only 2Health News:Ethane Web Technologies Announces 10% Christmas Discount on PPC Service 2
... team of doctors in Himachal Pradesh have removed an 18 ... was performed Wednesday at a hospital in Kullu, 240 km ... in Mandi district had reported at the hospital with pain ... 90 minutes to remove the hard oval shaped tumour from ...
... findings of a study shed light on a nagging mystery ... contain// considerable pools of free zinc ions. Zinc - a ... regulate neuronal signaling in the brain and spinal cord – ... a mutation affecting a neuronal zinc target, researchers have demonstrated ...
... to the general public as the number of reported infections ... Daily said// Wednesday. ,The latest statistics from the ... to 183,733 this year, up from 144,089 at the end ... 40,667 have developed into AIDS. ,"Health officials attributed ...
... called bivalirudin (Angiomax) that beats the standard combination drug ... heart// attacks. This new blood thinner seems to be ... ,The Results of the ‘Acute Catheterization and ... November issue of the New England Journal of Medicine. ...
... a widely used medication to strengthen fragile, aging bones ... recent study led by Johns Hopkins// rheumatologist Clifton Bingham, ... might be used to treat osteoarthritis after noticing that ... of drugs, not only slowed joint damage in animals, ...
... and adolescents are enjoying the health and social ... observers have noted problems related to// over-competitiveness and ... alarming increases in sport-related injuries in young athletes. ... Sport Medicine is a special Thematic Issue providing ...
Cached Medicine News:Health News:Zinc – A New Key Player In Brain Circuitr 2Health News:Alarming Rise in HIV Cases in China: Report 2Health News:New Anti-Clotting Drug Less Risky For Heart Attack Patients 2Health News:Millions with Arthritis May Benefit from Bone Loss Drug 2Health News:Kids in Sport—Great for Fitness, but Concern About Injurie 2Health News:Kids in Sport—Great for Fitness, but Concern About Injurie 3
Cross action, round handle, maximum opening 2.8 mm....
Irrigating nucleus chopper, 1.5 mm long wedge-shaped, inferior edge with round end, 0.6 mm dual sideports 20 gauge....
Phaco chopper elongated Kuglen style push-pull tip with wedge shaped superior and inferior edges. For bi-directional chopping....
... Floor Plates feature a unique design for ... a CP titanium and .3mm thick for ... for optimal malleability. Universal (left/right) anatomical shape ... out and smooth construction for optimal safety. ...
Medicine Products: